MicroRNAome genome: A treasure for cancer diagnosis and therapy

CA Cancer Journal for Clinicians

Volumn 64, Issue 5, 2014, Pages 311-336

  Berindan Neagoe, Ioana ^a   Monroig, Paloma Del C ^b,c   Pasculli, Barbara ^c,d   Calin, George A ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Cancer; Diagnosis; microRNA; Therapy

Indexed keywords

ANTAGOMIR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYCLOPHOSPHAMIDE; DNA DIRECTED RNA POLYMERASE III; FLUDARABINE; GLUCOCORTICOID; MICRORNA; MRX 34; RIBOZYME; RITUXIMAB; RNA POLYMERASE II; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; APOPTOSIS; BINDING SITE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER OF UNKNOWN PRIMARY SITE; CANCER THERAPY; CARCINOGENESIS; CATALYSIS; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DISEASE MARKER; DRUG TOLERABILITY; ENERGY METABOLISM; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE REPLICATION; GENETIC VARIABILITY; GENOME; GERMLINE MUTATION; GLIOBLASTOMA; HEPATITIS C; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MULTIPLE CANCER; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; ONCOLOGY; OPEN READING FRAME; OVARY CANCER; OVERALL SURVIVAL; POINT MUTATION; PROSTATE CANCER; PROTEIN BINDING; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA SEQUENCE; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TRANSLATIONAL RESEARCH; TUMOR INVASION; TUMOR MICROENVIRONMENT; UBIQUITINATION; UNTRANSLATED REGION; CANCER.; DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; MUTATION; NEOPLASM; PHYSIOLOGY; THERAPY;

CANCER.; DIAGNOSIS; MICRORNA; THERAPY;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; HUMANS; MICRORNAS; MUTATION; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908125804     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21244     Document Type: Review

References (221)

1. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113:673-676.
2. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15:R17-R29.
3. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577-4587.
4. Calin GA, Liu CG, Ferracin M, et al. Ultra-conserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007;12:215-229.
5. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011;146:353-358.
6. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007; 318:1931-1934.
7. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006;13: 1097-1101.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
9. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297:2056-2060.
10. Ambros V. The evolution of our thinking about microRNAs. Nat Med. 2008;14: 1036-1040.
11. Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science. 2007;315:97-100.
12. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA. 2008;105:1608-1613.
13. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 2008;455:1124-1128.
14. Forman JJ, Legesse-Miller A, Coller HA. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci USA. 2008;105:14879-14884.
15. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5 UTR as in the 3 UTR. Proc Natl Acad Sci USA. 2007;104:9667-9672.
16. Eiring AM, Harb JG, Neviani P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140: 652-665.
17. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467-477.
18. Yang M, Chen J, Su F, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer. 2011;10:117.
19. Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013;288:34343-34351.
20. Fabbri M, Paone A, Calore F, et al. Micro-RNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA. 2012;109:E2110-E2116.
21. Lehmann SM, Kruger C, Park B, et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurode-generation. Nat Neurosci. 2012;15:827-835.
22. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172-1187.
23. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-866.
24. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269.
25. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA. 2006;103:7024-7029.
26. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467:86-90.
27. Calin GA, Dumitru C, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524-15529.
28. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14: 1271-1277.
29. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28-40.
30. Callegari E, Elamin BK, Giannone F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012;56:1025-1033.
31. Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett. 2014; 588:99-104.
32. Gits CM, van Kuijk PF, Jonkers MB, et al. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. Br J Cancer. 2013;109:1625-1635.
33. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482:347-355.
34. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305:59-67.
35. Psathas JN, Thomas-Tikhonenko A. MYC and the srt of microRNA maintenance [published online ahead of print April 21, 2014]. Cold Spring Harb Perspect Med. doi: 10.1101/cshperspect.a014175.
36. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M. A microRNA component of the hypoxic response. Cell Death Differ. 2008; 15:667-671.
37. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9:293-302.
38. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999-3004.
39. Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Onco-gene. 2012;31:1609-1622.
40. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011;11:644-656.
41. Melo SA, Esteller M. Disruption of micro-RNA nuclear transport in human cancer [published online ahead of print March 7, 2014]. Semin Cancer Biol. doi: 10.1016/j.semcancer. 2014.02.012.
42. Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol. 2006;33:167-173.
43. Calin GA, Ferracin M, Cimmino A, et al. MicroRNA signature associated with prognosis and progression in chronic lympho-cytic leukemia. N Engl J Med. 2005;353: 1793-1801.
44. Auyeung VC, Ulitsky I, McGeary SE, Bartel DP. Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing. Cell. 2013;152:844-858.
45. Raveche ES, Salerno E, Scaglione BJ, et al. Abnormal microRNA-16 locus with syn-teny to human 13q14 linked to CLL in NZB mice. Blood. 2007;109:5079-5086.
46. Preskill C, Weidhaas JB. SNPs in micro-RNA binding sites as prognostic and predictive cancer biomarkers. Crit Rev Oncol. 2013;18:327-340.
47. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 2013;91:431-437.
48. Redis RS, Calin S, Yang Y, You MJ, Calin GA. Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther. 2012;136:169-174.
49. Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem. 2012;287:1397-1405.
50. Aucher A, Rudnicka D, Davis DM. Micro-RNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation. J Immunol. 2013;191:6250-6260.
51. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angio-genic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013;288:10849-10859.
52. Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol. 2007;27:1859-1867.
53. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
54. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
55. Negrini M, Nicoloso MS, Calin GA. Micro-RNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21:470-479.
56. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: microRNAs in cancer. Cell. 2009;137:586-586.e1.
57. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 micro-RNA family. Cell. 2005;120:635-647.
58. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315:1576-1579.
59. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21:1025-1030.
60. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7:759-764.
61. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435:839-843.
62. Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272-286.
63. Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282:2135-2143.
64. Xie L, Ushmorov A, Leithauser F, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119: 3503-3511.
65. Razumilava N, Bronk SF, Smoot RL, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in chol-angiocarcinoma. Hepatology. 2012;55:465-475.
66. Wei JS, Song YK, Durinck S, Chen QR, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene. 2008;27:5204-5213.
67. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuro-blastoma cells. Oncogene. 2007;26:5017-5022.
68. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298-1307.
69. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745-752.
70. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130-1134.
71. Li Q, Wang JX, He YQ, et al. MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis. 2014;5:e1197.
72. Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA. 2011;108:522-527.
73. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124:1169-1181.
74. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67:11001-11011.
75. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283:15878-15883.
76. Zheng Y, Li S, Ding Y, et al. The role of miR-18a in gastric cancer angiogenesis. Hepatogastroenterology. 2013;60:809-1813.
77. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682-688.
78. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28:341-347.
79. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120:298-1309.
80. Meng W, Ye Z, Cui R, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res. 2013;19:5423-5433.
81. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325-337.
82. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297-308.
83. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458: 762-765.
84. Rathore MG, Saumet A, Rossi JF, et al. The NF-kappaB member p65 controls glu-tamine metabolism through miR-23a. Int J Biochem Cell Biol. 2012;44:1448-1456.
85. Eichner LJ, Perry MC, Dufour CR, et al. miR-378(∗) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERR-gamma transcriptional pathway. Cell Metab. 2010;12:352-361.
86. Fang R, Xiao T, Fang Z, et al. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem. 2012;287:23227-23235.
87. Wei J, Wang F, Kong LY, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of gli-oma. Cancer Res. 2013;73:3913-3926.
88. De Planell-Saguer M, Rodicio MC. Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta. 2011;699:134-152.
89. Van Roosbroeck K, Pollet J, Calin GA. miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn. 2013;13:183-204.
90. Benes V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods. 2010;50:244-249.
91. Heneghan HM, Miller N, Kerin MJ. MiR-NAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 2010;10: 543-550.
92. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012;13:358-369.
93. Liu CG, Calin GA, Volinia S, Croce CM. MicroRNA expression profiling using microarrays. Nat Protoc. 2008;3:563-578.
94. Kloosterman WP, Wienholds E, De Bruijn E, Kauppinen S, Plasterk RH. In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes. Nat Methods. 2006;3:27-29.
95. Sempere LF, Preis M, Yezefski T, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. Clin Cancer Res. 2010;16:4246-4255.
96. Ferdin J, Kunej T, Calin GA. Non-coding RNAs: identification of cancer-associated microRNAs by gene profiling. Technol Cancer Res Treat. 2010;9:123-138.
97. Sempere LF, Korc M. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol. 2013;980:43-59.
98. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011;717:85-90.
99. Busk PK. A tool for design of primers for microRNA-specific quantitative RT-qPCR. BMC Bioinformatics. 2014;15:29.
100. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colo-rectal cancer. BMC Cancer. 2010;10:173.
101. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14:844-852.
102. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145-156.
103. Mulrane L, Klinger R, McGee SF, Gallagher WM, O'Connor DP. microRNAs: a new class of breast cancer biomarkers. Expert Rev Mol Diagn. 2014;14:347-363.
104. Wang J, Zhao J, Shi M, et al. Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9:e89223.
105. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138: 1659-1666.
106. Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem. 2013;59:1489-1496.
107. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel bio-marker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011; 6:e17745.
108. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127: 118-126.
109. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastro-enterol Hepatol. 2010;25:1674-1680.
110. Toiyama Y, Hur K, Tanaka K, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259:735-743.
111. Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9:e92921.
112. Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;110: 2291-2299.
113. Tsujiura M, Komatsu S, Ichikawa D, et al. Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer [published online ahead of print March 14, 2014]. Gastric Cancer. doi 10.1007/s10120-014-0363-1.
114. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50:136-142.
115. Lin Q, Chen T, Lin Q, et al. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol. 2013;107:767-771.
116. Rodriguez M, Silva J, Lopez-Alfonso A, et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer [published online ahead of print April 25, 2014]. Genes Chromosomes Cancer. doi: 10.1002/gcc. 22181.
117. Yang C, Wang C, Chen X, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive bio-markers for malignant astrocytomas. Int J Cancer. 2013;132:116-127.
118. Westermann AM, Schmidt D, Holdenrieder S, et al. Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. Anticancer Res. 2014; 34:665-669.
119. Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic bio-markers for ovarian cancer. PLoS One. 2013;8:e77853.
120. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
121. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71:326-331.
122. Hu Z, Chen X, Zhao Y, et al. Serum micro-RNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721-1726.
123. Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther. 2007;6:1483-1491.
124. Munker R, Calin GA. MicroRNA profiling in cancer. Clin Sci (Lond). 2011;121:141-158.
125. Boeri M, Pastorino U, Sozzi G. Role of MicroRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 2012;18:268-274.
126. Song JH, Meltzer SJ. MicroRNAs in patho-genesis, diagnosis, and treatment of gas-troesophageal cancers. Gastroenterology. 2012;143:35-47.
127. Zheng H, Liu JY, Song FJ, Chen KX. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med. 2013;10: 123-130.
128. Di Leva G, Croce CM. The role of micro-RNAs in the tumorigenesis of ovarian cancer. Front Oncol. 2013;3:153.
129. Gailhouste L, Ochiya T. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Histol Histopathol. 2013;28: 437-451.
130. Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood. 2009;114:4761-4770.
131. Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, Pichler M. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34: 557-564.
132. Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16:430-441.
133. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarci-noma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011;17:1875-1882.
134. Boeri M, Verri C, Conte D. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108:3713-3718.
135. Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014;32:768-773.
136. Wang Y, Gu J, Roth JA, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 2013; 73:4801-4809.
137. Volinia S, Croce CM. Prognostic micro-RNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci USA. 2013;110: 7413-7417.
138. Gasparini P, Cascione L, Fassan M, et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014; 5:1174-1184.
139. Chan M, Liaw CS, Ji SM, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013;19:4477-4487.
140. Kodahl AR, Lyng MB, Binder H, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study [published online ahead of print March 16, 2014]. Mol Oncol.
141. Mutch MG. Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol. 2007;96:693-703.
142. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299:425-436.
143. Kulda V, Pesta M, Topolcan O, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet. 2010;200:154-160.
144. Hansen TF, Sorensen FB, Lindebjerg J, Jakobsen A. The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxalipla-tin in patients with metastatic colorectal cancer. BMC Cancer. 2012;12:83.
145. Ma Y, Zhang P, Wang F, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61:1447-1453.
146. Kanaan Z, Roberts H, Eichenberger R, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013;258:400-408.
147. Giraldez MD, Lozano JJ, Ramirez G, et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastronenterol Hepatol. 2013;11:681-688.
148. Gomez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol. 2010; 118:88-92.
149. Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defines chemoresist-ance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA. 2013;110:9845-9850.
150. Leskela S, Leandro-Garcia LJ, Mendiola M, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2010;18:85-95.
151. Marchini S, Cavalieri D, Fruscio R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 2011;12:273-285.
152. Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23:86-199.
153. Kim TM, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by microRNAs. Cancer Res. 2011;71:3387-3399.
154. Li Y, Xu J, Chen H, et al. Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression. Nucleic Acids Res. 2013;41:e203.
155. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 2012; 14:29-33.
156. Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One. 2013;8:e78115.
157. Teplyuk NM, Mollenhauer B, Gabriely G, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012;14:689-700.
158. Manterola L, Guruceaga E, Gallego Perez-Larraya J, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014;16:520-527.
159. Rossi S, Shimizu M, Barbarotto E, et al. MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116:945-952.
160. Moussay E, Wang K, Cho JH, et al. Micro-RNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2011;108:6573-6578.
161. Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122:1891-1899.
162. Havelange V, Ranganathan P, Geyer S, et al. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 2014;123:2412-2415.
163. Rucker FG, Russ AC, Cocciardi S, et al. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia. 2013;27:353-361.
164. Marcucci G, Maharry KS, Metzeler KH, et al. Clinical role of microRNAs in cytoge-netically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013;31:2086-2093.
165. Diaz-Beya M, Brunet S, Nomdedeu J, et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute mye-loid leukemia. Leukemia. 2014;28:804-812.
166. Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential bio-markers for detecting acute myeloid leukemia. PLoS One. 2013;8:e56718.
167. Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104:19971-19976.
168. de Oliveira JC, Scrideli CA, Brassesco MS, et al. Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res. 2012;36:293-298.
169. Yan J, Jiang N, Huang G, et al. Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. Br J Haematol. 2013;163:93-103.
170. Wu P, Agnelli L, Walker BA, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 2013;162:348-359.
171. Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gamm-opathy of undetermined significance. Hae-matologica. 2014;99:511-518.
172. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lym-phoma. 2013;54:189-191.
173. Ferracin M, Pedriali M, Veronese A, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol. 2011;225:43-53.
174. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26:462-469.
175. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor origin. Mod Pathol. 2010;23:814-823.
176. Zion O, Burnstein I, Chajut A, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 2012;17:801-812.
177. Pentheroudakis G, Pavlidis N, Fountzilas G, et al. Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. Mol Cancer. 2013;12:57.
178. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9:775-789.
179. Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res. 2012;18:4234-4239.
180. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12:847-865.
181. TM (G3139; Bcl-2 Antisense Oligonucleo-tide) in Patients With Previously Treated Non-Small Cell Lung Cancer. NLM Identifier: NCT00030641. clinicaltrials.gov/show/NCT00030641. Accessed May 7, 2014.
182. Isis Pharmaceuticals. A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers. NLM Identifier: NCT01563302. clinicaltrials. gov/ct2/show/NCT01563302. Accessed May 7, 2014.
183. Hoosier Oncology Group. The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Oncology Group GU12-160. NLM Identifier: NCT01780545. clinicaltrials. gov/ct2/show/NCT01780545. Accessed May 7, 2014.
184. AstraZeneca. A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Met-astatic Hepatocellular Carcinoma. NLM Identifier: NCT01839604. clinicaltrials. gov/ct2/show/NCT01839604. Accessed May 7, 2014.
185. Ribozyome Pharmaceuticals Incorporated. A Phase II, Open-Label, Multicenter Trial of Angiozyme in Subjects With Metastatic Renal Cell Cancer. NLM Identifier: NCT00021021. http://clinicaltrials.gov/ct2/show/NCT00021021?term5%22Angiozyme %22&rank51. Accessed May 7, 2014.
186. Xiangya Hospital of Central South University. Phase I/II Study of EBV-LMP1 Targeted DNAzyme in Nasopharyngeal Carcinoma. NLM Identifier: NCT01449942. clinicaltrials.gov/ct2/show/NCT01449942. Accessed May 7, 2014.
187. The University of Texas MD Anderson Cancer Center. EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial. NLM Identifier: NCT01591356. clinicaltrials. gov/ct2/show/NCT01591356?term5%22 sirna%221AND1%22Cancer%22&rank51. Accessed May 7, 2014.
188. Scott Pruitt, Duke University Medical Center. Phase I Study of Active Immunother-apy of Metastatic Melanoma With Mature Autologous Dendritic Cells Transfected With Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing. NLM Identifier: NCT00672542. clinicaltrials.gov/ct2/show/NCT00672542. Accessed May 7, 2014.
189. Dicerna Pharmaceuticals Inc. Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lym-phoma. NLM Identifier: NCT02110563. clin-icaltrials.gov/ct2/show/NCT02110563. Accessed May 7, 2014.
190. Hadassah Medical Center. Use of SV40 siRNA Vectors to Treat CML. NML Identifier: NCT00257647. clinicaltrials.gov/show/NCT00257647. Accessed May 7, 2014.
191. Mirna Therapeutics Inc. A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension. NLM Identifier: NCT01829971. clinical-trials.gov/ct2/show/NCT01829971?term5 MRX34&rank51. Accessed May 7, 2014.
192. Santaris Pharma A/S. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacoki-netics and Antiviral Activity of SPC3649 (Miravirsen) Administered to Treatment-Naive Subjects With Chronic Hepatitis C (CHC) Infection. NLM Identifier: NCT01200420. clinicaltrials.gov/ct2/show/NCT01200420?term5miravirsen&rank53. Accessed May 7, 2014.
193. Enzon Pharmaceuticals Inc. A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oli-gonucleotide Against Hypoxia-Inducible Factor-1a, Administered as a Weekly 2Hour Intravenous Infusion in Adult Patients With Advanced Solid Tumors or Lymphoma. NLM Identifier: NCT00466583. clinicaltrials.gov/ct2/show/NCT00466583. Accessed May 7, 2014.
194. Santaris Pharma A/S. An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996, an LNA Anti-sense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lym-phocytic Leukaemia. NLM Identifier: NCT00285103. clinicaltrial.gov/ct2/show/NCT00285103?term5%22SPC2996%22 &rank51. Accessed May 7, 2014.
195. Enzon Pharmaceuticals Inc. T2009-007: A Phase I Study Evaluating the Safety, Toler-ability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) [IND 108753]. NML Identifier: NCT01186328. clinicaltrial.gov/ct2/show/NCT01186328?term=%22EZN3042% 22&rank=1. Accessed May 7, 2014.
196. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA. 2008;105:5166-5171.
197. Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nano-particles. PLoS One. 2012;7:e38129.
198. Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
199. Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine. 2013;8:61-71.
200. Wu Y, Crawford M, Mao Y, et al. Therapeutic delivery of microRNA-29b by cati-onic lipoplexes for lung cancer. Mol Ther Nucleic Acids. 2013;2:e84.
201. Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol. 2012;199:407-412.
202. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685-1694.
203. Freireich EJ, Frei E 2nd. Recent advances in acute leukemia. Prog Hematol. 1964;4: 187-202.
204. Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2011;7: 765-774.
205. Nishimura M, Jung EJ, Shah MY, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013;3:1302-1315.
206. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904-914.
207. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145-166.
208. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12: 433-446.
209. Schonrock N, Harvey RP Mattick JS. Long noncoding RNAs in cardiac development and pathophysiology. Circ Res. 2012;111: 1349-1362.
210. Iaconetti C, Gareri C, Polimeni A, Indolfi C. Non-coding RNAs: the "dark matter" of cardiovascular pathophysiology. Int J Mol Sci. 2013;14:19987-20018.
211. Li Z, Chao TC, Chang KY, et al. The long noncoding RNA THRIL regulates TNFa expression through its interaction with hnRNPL. Proc Natl Acad Sci USA. 2014; 111:1002-1007.
212. Cui H, Xie N, Tan Z, et al. The human long noncoding RNA, lnc-IL7R, regulates inflammatory response [published online ahead of print April 11, 2014]. Eur J Immunol. doi: 10.1002/eji. 201344126.
213. Yan B, Tao ZF, Li XM, Zhang H, Yao J, Jiang Q. Aberrant expression of long noncoding RNAs in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014;55:941-951.
214. Guay C, Jacovetti C, Nesca V, Motterle A, Tugay K, Regazzi R. Emerging roles of non-coding RNAs in pancreatic b-cell function and dysfunction. Diabetes Obes Metab. 2012;14(suppl 3):12-21.
215. Faghihi MA, Modarresi F, Khalil AM. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14:7237-7230.
216. Scaria V, Pasha A. Long non-coding RNAs in infection biology. Front Genet. 2013;3: 308.
217. Barry G, Briggs JA, Vanichkina DP, Poth EM. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing. Mol Psychiatry. 2014;19:486-494.
218. Dharap A, Nakka VP, Vemuganti R. Effect of focal ischemia on long noncoding RNAs. Stroke. 2012;43:2800-2802.
219. Cabianca DS, Casa V, Bodega B, et al. A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell. 2012; 149:819-831.
220. Carpenter S, Aiello D, Atianand MK. A long noncoding RNA mediates both activation and repression of immune response genes. Science. 2013;341:789-792.
221. Imamura K, Imamachi N, Akizuki G. Long noncoding RNA NEAT1-dependent SFPQ relocation from promoter region to para-speckle mediates IL8 expression upon immune stimuli. Mol Cell. 2014;53: 393-406.